Electroencephalographic Biomarker to Predict Acute Post-operatory Cognitive Dysfunction

Cognitive Dysfunction Clinical Trial

Official title:

Electroencephalographic Biomarker to Predict the Development of Acute Post-operatory Cognitive Dysfunction States: a Protocol of an Observational Study in a Cohort of Patients From Two Centers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04214496
• Other study ID #: ID19I10345
• Status: Completed
• Start date: January 4, 2021
• Est. completion date: August 4, 2022

Study information

• Verified date: August 2023
• Source: University of Chile
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Acute post-operatory cognitive dysfunction states are one of the most important complications in older patients after surgery. Two acute cognitive dysfunctions have been described: postoperative delirium (PD) and postoperative subsyndromal delirium (PSSD). Patients who develop delirium, both as a complete or incomplete syndrome, have poor long-term outcomes, such as longer length of hospital stay, institutionalization at discharge, and even higher mortality, and consequently, the human and economic costs significantly increase for the health system. Here the research team will use an observational cohort, investigator blinded in two-center with a primary endpoint to validate the relative alpha power ratio as a predictive biomarker of postoperative cognitive dysfunctions.

Description:

Acute post-operatory cognitive dysfunction states are one of the most important complications in older patients after surgery. Two acute cognitive dysfunctions have been described: postoperative delirium (PD) and postoperative subsyndromal delirium (PSSD). In previous reports, the incidence of PD in older patients is between 10% to 30%, while PSSD is more frequent 30% to 50%. Patients who develop delirium, both as a complete or incomplete syndrome, have poorer long-term outcomes, such as longer length of hospital stay, institutionalization at discharge, and even higher mortality, and consequently, the human and economic costs significantly increase for the health system. An early diagnostic and prevention of delirium are the key points to decrease the poor long-term outcomes and health costs. The diagnosis requires cognitive testing to elucidate functional patients' status before and after surgery. The need for a biomarker that may predict the occurrence of PD and PSSD and allow the selection of patients who need prevention strategies is a primary research field. Here the research team will use an observational cohort, investigator blinded in two-center with a primary endpoint to validate the relative alpha power ratio as a predictive biomarker of postoperative cognitive dysfunctions. To calculate the sample size, the investigators used values obtained from a previous work in a cohort of 30 patients and decided to compare the prediction ability of MoCA and alpha power ratio. ROC curves and their AUC were used to calculate the prediction ability of MoCA and alpha power ratio. Thus, a sample size of 425 patients was calculated considering an AUC of MoCA = 0.786 and AUC of alpha power = 0.895, a two-tailed test, an alpha error of 0.05 and a power of 0.8 and considering a 25% loss. Investigators consider this study as a pilot validation trial to establish the utility and the capacity of the EEG biomarker for predicting PD and PSSD, the research team aims to include the 25% of the total sample. This yields the need for 106 patients for this preliminary trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: August 4, 2022
• Est. primary completion date: August 4, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Age = 60 years old
• Scheduled for high-risk elective surgery
• Need for at least 3 days of hospital stay
• Surgery performed under general anesthesia
• Written informed consent for participation in the trial

Exclusion Criteria:

• Patients with preoperative delirium or dementia
• Patients using neuroleptics drug during the past 6 months
• Patients with a history of encephalopathy, psychosis, stroke or brain trauma with neurologic sequels
• The use of ketamine or dexmedetomidine during surgery
• Emergency surgery
• Mechanical ventilation during the 72 after surgery
• Analphabetism
• Patients who do not talk Spanish
• Patients included in another clinical trial

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Delirium
• Emergence Delirium
• Postoperative Delirium

Intervention

Device:
• Sedline
Intraoperative EEG monitorization

Locations

Country	Name	City	State
Chile	Hospital Clinico Universidad de Chile	Santiago
Chile	Instituto Nacional del Cancer	Santiago

Sponsors (2)

Lead Sponsor	Collaborator
University of Chile	Masimo Corporation

Country where clinical trial is conducted

Chile, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Delirium and Subsyndromal Delirium	Incidence of Delirium and Subsyndromal Delirium in the cohort	5 Postoperative days
Secondary	Death	Number of deceased patients	Perioperative period
Secondary	Delirium Severity	Delirium severity assessed by Cognitive Assessment Method - Severity	5 Postoperative days
Secondary	Delirium Duration	Duration of delirium during the perioperative period	Perioperative period
Secondary	Need for Mechanical Ventilation assistance	Number of patients that needed mechanical ventilation	Perioperative period
Secondary	Reintervention	Number of patients that needed another surgery after primary intervention	Perioperative period
Secondary	Unanticipated ICU hospitalization	Number of patients that needed unanticipated intensive care unit (ICU) care	Perioperative period